MitraClip

A better quality of
life is possible for your
patients with MR

MitraClip Therapy: A Minimally Invasive Option

MitraClip transcatheter mitral valve repair (TMVr) is a minimally invasive treatment option for patients with significant mitral regurgitation (MR) who are considered at high surgical risk.1

For Many, Surgery Is Contraindicated and Medications Are Not Sufficient

Approximately 50% of symptomatic patients with severe MR are not candidates for surgery due to underlying factors.* MR patients who most need intervention are often the most likely to be denied surgery.2

*Based on a survey of severely symptomatic MR patients in NYHA Class III-IV (n = 396); 10% had surgery the following year.
The remainder had no surgery; medical management only.

MitraClip Makes Intervention Possible for Your Patients with MR

Considerations for MitraClip candidates include:1

  • Significant MR (MR ≥ 3+)
  • Symptomatic
  • High-surgical-risk factors including age, frailty, or severe comorbidities such as liver disease and pulmonary hypertension

ACC/AHA and ESC/EACTS Guidelines Favor Intervention

MitraClip is the only TMVr therapy recommended by 2017 AHA/ACC, 2016 ESC/HF, and 2017 ESC/EACTS Guidelines.3-5 Determining the severity of MR is an important factor in the management of the condition. The guidelines support aggressive monitoring and early action, with the goal of preventing complications due to LV volume overload.3

SCREENING TOOLS TO DETERMINE IF MITRACLIP IS AN APPROPRIATE TREATMENT OPTION FOR YOUR PATIENT

For HealthCare Professionals in EMEA
 

AdvancedHeartTherapies.com

MitraClip Transthoracic Echo (TTE) Screening Guide
 

DOWNLOAD NOW

AP2947039-WBO Rev. A

References
  1. MitraClip NTR XTR Clip Delivery System Instructions for Use.
  2. Mirabel M, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358-1365.
  3. Baumgartner H, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(21):2739-2791.
  4. Nishimura RA. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;136(9):1–123. DOI: 10.1161/CIR.0000000000000503.
  5. Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.
     

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.